March 5, 2024
Global Scopolamine Market

Scopolamine Market poised to Propelled by increasing prevalence of motion sickness

Scopolamine is increasingly used for preventing motion sickness due to conditions like seasickness or airsickness. It acts on the vestibular system in the inner ear, which controls balance and motion sensing, and helps block signals to the brain that cause nausea and vomiting. The anti-nausea effects of scopolamine have made it a preferred treatment option for patients requiring nerve blocks before surgeries or suffering from gastrointestinal disorders that cause excessive vomiting.

The global scopolamine market is estimated to be valued at US$ 3676.85 Bn  in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Increasing prevalence of motion sickness is a key driver augmenting the scopolamine market growth over the forecast period. As per studies, around 50% population experience motion sickness while travelling. Rising number of people travelling by air, sea or car has escalated the cases of motion sickness worldwide. Moreover, growing awareness about effective medications like scopolamine patches has spur further demand. Manufacturers are focused on developing novel transdermal delivery systems like patches and gels with enhance absorption capabilities to boost adoption of scopolamine products for long lasting relief. New research studies evaluating scopolamine efficacy against serious motion sickness is also pushing market expansion. For instance, in 2021, a research showed scopolamine patch was effective in preventing sickness even during vigorous physical activities in naval cadets. Such findings have strengthened scopolamine position in military, travel and health sectors.

SWOT Analysis

Strength: Scopolamine market has growth due to expanding applications in neurosurgery and pain management. It provides an alternative and effective treatment option compared to opioids.

Weakness: Possible side effects associated with scopolamine such as blurred vision, dry mouth, and confusion in elderly. Requirement of close monitoring during treatment.

Opportunity: Growing geriatric population suffering from neurological disorders and post-surgical pain indications. Development of novel delivery formulations can improve safety profile of scopolamine.

Threats: Stringent regulatory environment. Availability of alternative treatment options. Reimbursement issues related to high costs.

Key Takeaways

Global Scopolamine Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global scopolamine market is estimated to be valued at US$ 3676.85 Bn  in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030.

Regional analysis comprises North America is currently dominating the market owing to increasing demand for pain management therapies and initiatives to curb opioid epidemic. The Asia Pacific region is expected register fastest growth due to growing healthcare expenditure and expanding base of neurological and chronic pain patient population.

Key players operating in the scopolamine market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it